|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al CONCORD Working Group, : Global surveillance of cancer
survival 1995–2009: Analysis of individual data for 25,676,887
patients from 279 population-based registries in 67 countries
(CONCORD-2). Lancet. 385:977–1010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Larsen JE and Minna JD: Molecular biology
of lung cancer: Clinical implications. Clin Chest Med. 32:703–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riely GJ, Pao W, Pham D, Li AR, Rizvi N,
Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M and Miller VA:
Clinical course of patients with non-small cell lung cancer and
epidermal growth factor receptor exon 19 and exon 21 mutations
treated with gefitinib or erlotinib. Clin Cancer Res. 12:839–844.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang J, Feng X, Zhou W, Wu Y and Yang Y:
MiR-128 reverses the gefitinib resistance of the lung cancer stem
cells by inhibiting the c-met/PI3K/AKT pathway. Oncotarget.
7:73188–73199. 2016.PubMed/NCBI
|
|
7
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kobayashi I, Takahashi F, Nurwidya F, Nara
T, Hashimoto M, Murakami A, Yagishita S, Tajima K, Hidayat M,
Shimada N, et al: Oct4 plays a crucial role in the maintenance of
gefitinib-resistant lung cancer stem cells. Biochem Biophys Res
Commun. 473:125–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gargalionis AN and Basdra EK: Insights in
microRNAs biology. Curr Top Med Chem. 13:1493–1502. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Y, He N, Dong Y and Jiang C:
MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin
treatment in osteosarcoma. Sci Rep. 6:342382016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye Z, Hao R, Cai Y, Wang X and Huang G:
Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by
targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol.
37:4509–4515. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chai S, Ng KY, Tong M, Lau EY, Lee TK,
Chan KW, Yuan YF, Cheung TT, Cheung ST, Wang XQ, et al: Octamer
4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in
liver cancer stem cells. Hepatology. 64:2062–2076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang H, Meng Y, Cui Q, Qin F, Yang H, Chen
Y, Cheng Y, Shi J and Guo Y: MiR-101 targets the EZH2/Wnt/β-catenin
the pathway to promote the osteogenic differentiation of human bone
marrow-derived mesenchymal stem cells. Sci Rep. 6:369882016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng X, Jiang J, Shi S, Xie H, Zhou L and
Zheng S: Knockdown of miR-25 increases the sensitivity of liver
cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad
signaling pathway. Int J Oncol. 49:2600–2610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee SO, Yang X, Duan S, Tsai Y, Strojny
LR, Keng P and Chen Y: IL-6 promotes growth and
epithelial-mesenchymal transition of CD133+ cells of
non-small cell lung cancer. Oncotarget. 7:6626–6638. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
French R, Hayward O, Jones S, Yang W and
Clarkson R: Cytoplasmic levels of cFLIP determine a broad
susceptibility of breast cancer stem/progenitor-like cells to
TRAIL. Mol Cancer. 14:2092015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murakami A, Takahashi F, Nurwidya F,
Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K,
Shimada N, et al: Hypoxia increases gefitinib-resistant lung cancer
stem cells through the activation of insulin-like growth factor 1
receptor. PLoS One. 9:e864592014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gadgeel SM and Wozniak A: Preclinical
rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for
epidermal growth factor receptor inhibitor-resistant non-small-cell
lung cancer. Clin Lung Cancer. 14:322–332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang T, Gong X, Jiang R, Li H, Du W and
Kuang G: Ferulic acid inhibits proliferation and promotes apoptosis
via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl
Res. 8:968–980. 2016.PubMed/NCBI
|
|
23
|
Wang R, Zhang Q, Peng X, Zhou C, Zhong Y,
Chen X, Qiu Y, Jin M, Gong M and Kong D: Stellettin B induces G1
arrest, apoptosis and autophagy in human non-small cell lung cancer
A549 cells via blocking PI3K/Akt/mTOR pathway. Sci Rep.
6:270712016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu YR, Qi HJ, Deng DF, Luo YY and Yang SL:
MicroRNA-21 promotes cell proliferation, migration, and resistance
to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal
cancer. Tumour Biol. 37:12061–12070. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu HA and Pao W: Targeted therapies:
Afatinib - new therapy option for EGFR-mutant lung cancer. Nat Rev
Clin Oncol. 10:551–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murakami A, Takahashi F, Nurwidya F,
Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K,
Shimada N, et al: Hypoxia increases gefitinib-resistant lung cancer
stem cells through the activation of insulin-like growth factor 1
receptor. PLoS One. 9:e864592014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qu WQ, Liu L and Yu Z: Clinical value of
microRNA-23a upregulation in non-small cell lung cancer. Int J Clin
Exp Med. 8:13598–13603. 2015.PubMed/NCBI
|
|
31
|
Zhou S, Huang Q, Zheng S, Lin K, You J and
Zhang X: miR-27a regulates the sensitivity of breast cancer cells
to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol.
37:6837–6845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yin W, Nie Y, Zhang Z, Xie L and He X:
miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent
pathway in HCC chemotherapy. Oncol Rep. 34:368–374. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang YS, Wang YH, Xia HP, Zhou SW,
Schmid-Bindert G and Zhou CC: MicroRNA-214 regulates the acquired
resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant
cell lines. Asian Pac J Cancer Prev. 13:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Darido C, Georgy SR, Wilanowski T, Dworkin
S, Auden A, Zhao Q, Rank G, Srivastava S, Finlay MJ, Papenfuss AT,
et al: Targeting of the tumor suppressor GRHL3 by a
miR-21-dependent proto-oncogenic network results in PTEN loss and
tumorigenesis. Cancer Cell. 20:635–648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma Y, Zhang P, Gao Y, Fan H, Zhang M and
Wu J: Evaluation of AKT phosphorylation and PTEN loss and their
correlation with the resistance of rituximab in DLBCL. Int J Clin
Exp Pathol. 8:14875–14884. 2015.PubMed/NCBI
|
|
37
|
Wang J, Xu J, Fu J, Yuan D, Guo F, Zhou C
and Shao C: MiR-29a regulates radiosensitivity in human intestinal
cells by targeting PTEN gene. Radiat Res. 186:292–301. 2016.
View Article : Google Scholar : PubMed/NCBI
|
